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Abstract
Introduction Microbleeds are associated with the development of dementia in older people and are common in Alzheimer’s 
disease (AD). Their prevalence and clinical importance in dementia with Lewy bodies (DLB) is unclear. The objective of this 
study was to compare the rates of microbleeds in DLB with those in AD and healthy older people, and investigate associa-
tions between microbleeds and amyloid deposition, vascular risk and disease severity in DLB.
Methods DLB (n = 30), AD (n = 18) and control (n = 20) participants underwent clinical assessment at baseline and 1 year 
in this longitudinal observational study. 3T MRI (including T2* susceptibility weighted imaging) and florbetapir PET were 
carried out at baseline. Microbleeds were rated visually and a standardised uptake value ratio (SUVR) was calculated from 
florbetapir PET scans.
Results 40% of DLB subjects had microbleeds compared with 50% of AD and 15% of controls. Compared to DLB without 
microbleeds, those with microbleeds had higher systolic BP (156 ± 26 v. 135 ± 19 mmHg; p = 0.03), but did not have greater 
levels of vascular disease or amyloid deposition (SUVR 1.25 ± 0.24 v. 1.25 ± 0.22; p = 0.33). There was evidence of less 
severe dementia in DLB participants with microbleeds, but these differences may have been driven by a shorter disease 
duration in those with microbleeds.
Conclusion The presence of microbleeds in DLB is associated with higher blood pressure, but not with other measures of 
vascular disease or amyloid deposition. The relationship between microbleeds and clinical presentation remains unclear.
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Introduction
Dementia with Lewy bodies is characterised by alpha-synu-
clein (αSyn) deposition in brainstem, limbic and cortical 
areas [1]. This is often accompanied by other pathologies 
such as amyloid [2], tau [3] and vascular pathology [4]. 
Certain types of vascular pathology, such as microinfarcts, 
atherosclerosis and cerebral amyloid angiopathy, are more 
common in synucleinopathy than in healthy controls [5]. In 
addition, white matter changes are more widespread in DLB 
than controls both on MRI and postmortem [6, 7], though 
these changes do not necessarily reflect vascular disease [8]. 
Infarcts on MRI and larger infarcts on postmortem do not 
appear to be more common in DLB than controls [5, 6]. The 
presence of vascular disease may have an additive effect on 
cognitive impairment in neurodegenerative diseases, as vas-
cular disease has been shown to be an independent predictor 
of dementia in both Alzheimer’s disease and synucleinopa-
thy [5].
Cerebral microbleeds are small foci of chronic blood 
products in normal or near normal brain tissue [9]. They 
appear as small hypointense areas on T2*-weighted MRI due 
to the presence of superparamagnetic haemosiderin. Micro-
bleeds can be classed as lobar (cortical or subcortical), deep 
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(basal ganglia, thalamus, internal capsule, external capsule, 
corpus callosum or deep/periventricular white matter) or 
infratentorial (brainstem or cerebellum) [10]. Lobar micro-
bleeds have also been shown to be associated with cortical 
amyloid deposition on PET amyloid imaging and the APOE 
ε4 allele, whereas deep microbleeds are associated with car-
diovascular risk factors [11–13].
The effect of microbleeds on cognition in dementia is 
unclear. Microbleeds are more common in AD than in 
healthy older people (odds ratio 2.1), but are not associated 
with differences in global cognition within AD [14]. The 
actual prevalence of microbleeds is difficult to ascertain as 
their detection increases with increased MR scanner field 
strength and the use of more sensitive imaging techniques 
such as susceptibility weighted imaging [14].
Microbleeds have been reported as being present in 
17–45% of cases of DLB [15–17]. Two studies have reported 
that microbleeds are present in similar proportions of DLB 
and AD cases [16, 17]. One study reported that microbleeds 
were associated with a trend towards less reduction in car-
diac MIBG binding, suggesting that vascular pathology was 
associated with less severe Lewy body pathology in DLB 
[16]. The distribution of microbleeds in DLB has differed 
between studies, though frontal microbleeds appear to be 
common. In contrast to findings in AD, a postmortem study 
in Lewy body dementia found that microbleeds were not 
more common in cases with AD pathology or cerebral amy-
loid angiopathy [18]. The clinical relevance of microbleeds 
in DLB is unclear.
Aims and hypotheses
The aim of this study was to compare the rates of micro-
bleeds in DLB with those in AD and healthy older people, 
and to compare the clinical and imaging findings of DLB 
with and without microbleeds. The hypotheses were that:
1. Microbleeds would be more common in DLB than 
healthy controls, at a rate similar to AD.
2. The presence of microbleeds in DLB would not be asso-
ciated with amyloid deposition.
3. DLB with microbleeds would be associated with greater 




Participants with dementia were recruited prospectively 
between June 2013 and February 2016 from secondary 
care services in the North of England. All participants 
were ≥ 60 years old and had a diagnosis of probable AD 
or probable DLB confirmed by two clinicians based on 
contemporaneous diagnostic criteria [19, 20], with an 
MMSE ≥ 12. Participants were recruited prior to the 
publication of the 2017 diagnostic criteria for DLB [1], 
but all DLB participants met the updated criteria for a 
diagnosis of probable DLB. Control participants were 
recruited through a research case register or were partners 
of participants.
Participants were excluded if they had a major concur-
rent psychiatric illness; severe physical illness; contraindi-
cations to PET-CT imaging or MRI; a history of other sig-
nificant neurological illness including stroke or previous 
experimental treatment with an amyloid-targeting agent.
Participants with capacity gave their written informed 
consent to take part in the study. For those who lacked 
capacity to participate, their participation in the study was 
discussed with a consultee in accordance with the Mental 
Capacity Act. The study received ethical approval from 
the National Research Ethics Service Committee North 
East—Newcastle and North Tyneside 2 (13/NE/0064).
Baseline cognitive and clinical assessment
Participants had a clinical and cognitive assessment car-
ried out at baseline and 1 year. The severity of cogni-
tive and functional impairment was assessed using the 
Addenbrooke’s Cognitive Examination-Revised (ACE-R) 
and the Bristol and Instrumental Activities of Daily Liv-
ing Scales (BADL, IADL). IADL and BADL scores were 
combined to make a composite function z-score where 
positive scores indicated greater impairment. The sever-
ity of parkinsonism and cognitive fluctuations were meas-
ured using the Revised Unified Parkinson’s disease Rating 
Scale Motor Sub-scale (UPDRS) and Clinician assessment 
of Fluctuation (CAF), respectively. Blood pressure was 
assessed with the participant lying at rest and then after 
standing for 2 min. Comorbidities including vascular dis-
ease were assessed using the Cumulative illness Rating 
Scale for Geriatrics (CIRS-G) [21].
Imaging
Imaging was performed at baseline. Details of the MRI 
and PET acquisition and analysis have been published 
elsewhere [22] and will briefly be summarised here.
Brain MRI scans were acquired using a 3T MR scanner 
(Achieva scanner; Philips Medical Systems), with body coil 
transmission and eight channel head coil receiver. Images 
acquired included a 3D sagittal magnetisation-prepared rapid 
gradient echo (MPRAGE) sequence (repetition time 8.3 ms, 
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echo time 4.6 ms, flip angle 8°, inversion delay 1250 ms, 
imaging time 4.5 mins, sagittal acquisition matrix 216 × 240, 
voxel size 1 × 1x1mm) and T2*-weighted sequence (TR 
1487 ms, TE 16.11 ms, flip angle 18°, 50 slices with 3 mm 
thickness (0 mm gap), voxel size 0.898 × 1.12 mm).
Amyloid imaging was carried out using a Siemens Bio-
graph-40 PET-CT scanner with data acquired in list mode. 
Participants were given a 370 MBq intravenous injection of 
18F-florbetapir (Amyvid), followed immediately by a 5 min 
scan for perfusion images, with a subsequent 15 min scan 
starting 30–50 min after injection to image amyloid distribu-
tion. Images were reconstructed using iterative reconstruc-
tion (4 iterations, 16 subsets), with a 168 × 168 matrix size, 
2.04 × 2.04 mm pixel size, 3 mm slice thickness, and 3 mm 
post-reconstruction Gaussian filter. Attenuation correction 
was performed utilising CT scan data.
Image processing
All analysis of MRI and PET images was performed using 
SPM 8 (www.fil.ion.ucl.ac.uk/spm/softw are/spm8/). MRI 
images were segmented into white matter, grey matter and 
CSF, and total intracranial volume was defined as the sum 
of these. White matter hyperintensity (WMH) segmentation 
was carried out using the FLAIR and T1 structural images 
using a semi-automated threshold-based algorithm employ-
ing SPM8 functions (www.fil.ion.ucl.ac.uk/spm) in an in-
house written Matlab package (Matlab R2013a, Mathworks, 
Inc., Natick, MA, USA) as described previously [23]. The 
resulting WMH masks were manually edited using ITK-
SNAP (www.itksn ap.org) to correct for minor errors.
Grey matter volume (GMV) and white matter hyperin-
tensities (WMH) were expressed relative to total intracranial 
volume. The log of WMH was used to normalise the data.
The amyloid PET image was co-registered with the native 
space MRI. A mean cortical standardised uptake value ratio 
(SUVR) was derived from the unweighted mean of frontal, 
temporal, parietal and cingulate regions relative to the whole 
cerebellum [24]. The perfusion region of interest SUVR was 
calculated from the early florbetapir images using a previ-
ously described method [22]. Hippocampal volumes were 
calculated using an automated technique [25].
The T2* images were processed to produce susceptibility 
weighted images (SWI) according to the method of Haacke 
using in-house Matlab software [26].
Visual rating
The SWI images were rated by an experienced neuroradiolo-
gist (DM) who was blind to diagnosis and all clinical and 
other imaging measures. The Microbleed Anatomical Rat-
ing Scale [10] was used to rate their presence, number and 
location for each subject. Microbleeds were classed as defi-
nite or possible, and defined as present in a subject if there 
was any microbleed (definite or possible) in any region.
Statistical analysis
Statistical analysis was completed using IBM SPSS Statis-
tics software (version 22; https ://www-03.ibm.com/softw 
are/produ cts/en/spss-stati stics ). Demographic comparisons 
between microbleed groups were carried out using t tests 
or Mann–Whitney tests. χ2 or Fisher’s exact tests were used 
for categorical variables. The association of the presence 
of microbleeds with clinical and imaging variables was 
assessed using linear regression with age included as an 
independent variable. Associations were measured at base-
line and follow-up. For follow-up measures, the dependent 
variable was rate of change of the measure, and baseline 
score was also included as an independent variable. Col-
linearity was excluded by ensuring correlation between 
independent variables was less than 0.7 and tolerance was 
greater than 0.1. The data were checked to ensure there were 
no outlying or influential values (standardised or studentised 
residual <  ± 3, leverage < 0.5, Cook’s Distance < 1). The 
normality of residuals was assessed by visual inspection of 
P–P plots of standardised residuals. Scatter plots of studen-
tised residuals against predicted values and partial regression 
plots were inspected to ensure the presence of linear rela-
tionships between the dependent and independent variables 
and homoscedasticity in the overall model. Subjects with 
missing data were excluded from each analysis. Sample size 
was calculated to investigate amyloid imaging in DLB, AD 
and controls as previously reported [22].
Results
A total of 87 participants agreed to enter the study, of which 
72 met the eligibility criteria and underwent a baseline 
assessment. Two DLB cases were later excluded due to non-
DLB pathological diagnosis; five DLB cases were confirmed 
by postmortem diagnosis. Two participants were unable to 
tolerate MRI. A total of 68 participants were included in this 
analysis (Table 1). DLB participants had significantly lower 
blood pressure than control participants. Both AD and DLB 
participants displayed predominantly lobar microbleeds.
DLB participants with microbleeds tended towards being 
older and having a shorter disease duration than those with-
out microbleeds and had higher resting systolic blood pres-
sure (Table 2). There were no differences in smoking history, 
gender, vascular disease history, postural blood pressure 
change, years in education or rates of APOE-ɛ4 allele.
DLB participants with microbleeds had greater parietal 
perfusion (Table 3). There were no differences between the 
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groups in grey matter volume, amyloid SUVR or white matter 
hyperintensities (Table 3). Similarly, those with specifically 
lobar microbleeds did not have a significantly higher amyloid 
SUVR (SUVR = 1.23 v. 1.25; Beta = − 0.12, p = 0.48).
DLB participants with microbleeds had better daily func-
tion scores and less severe parkinsonism (Table 4). When 
the duration of dementia was included as a covariate, the 
relationship with baseline function remained significant, 
whereas the relationships with baseline UPDRS (p = 0.08) 
and parietal perfusion (p = 0.07) were no longer significant.
23/30 DLB participants completed the 1-year follow-up. 
Of those that did not undertake follow-up assessment, four 
had died, one had a severe stroke and two withdrew from the 
study. Those that did not complete follow-up tended towards 
being older and having more severe cognitive impairment. 
Four had microbleeds and three did not. One participant was 
unable to complete the ACE and another was unable to com-
plete the UPDRS at follow-up. Participants with microbleeds 
had significantly less progression in parkinsonism measured 
by the UPDRS, though there was little change in the score 
in either group (Supplementary Table 1).
Assumption checking for linear regression
There was a single significant outlier in baseline function 
and parietal perfusion analyses, but in both cases removing 
this subject had no effect on the result.
Discussion
The aim of this study was to compare the rates of microbleeds 
in DLB with those in AD and healthy older people, and to 
compare the clinical and imaging findings of DLB with and 
without microbleeds. The prevalence of microbleeds in DLB 
was intermediate between controls and Alzheimer’s disease 
and was not statistically significantly different to either group. 
The lobar pattern of microbleeds in AD and DLB was in 
keeping with previous reports [15, 17, 27, 28], though one 
study has reported more deep microbleeds in DLB [16].
This is the first study to report both amyloid imaging and 
microbleeds in DLB and there was no evidence of increased 
amyloid deposition in the DLB participants with micro-
bleeds. Our findings are in keeping with those from a small 
postmortem DLB cohort, which reported no increase in 
microbleeds in brains of people with DLB and concomitant 
Table 1  Demographics and 
microbleed results in DLB, AD 
and controls
Mean (SD) or n (%) where specified
Bold denotes p < 0.05. Bonferroni correction for post hoc comparisons
MB microbleed
a Significant control v AD
b Significant control v DLB
Diagnosis Control AD DLB Statistic p
n 20 18 30 – –
Age 75.9 (7.3) 75.8 (7.1) 76.2 (7.0) F < 0.1 0.98
Sex [n, (%) female] 4 (20%) 2 (11%) 7 (23%) χ2 = 1.1 0.58
Smoking pack years 12.9 (21.5) 7.4 (15.2) 11.3 (20.8) H = 0.2 0.88
Duration of dementia (months) – 24.1 (21.8) 20.1 (19.4) U = 242 0.54
On antiplatelet or warfarin [n (%)] 10 (50%) 3 (17%) 14 (47%) χ2 = 5.5 0.06
On antihypertensive [n (%)] 12 (60%) 11 (61%) 14 (47%) χ2 = 1.3 0.52
BP Lying systolic (mmHg) 160.5 (26.6) 141.2 (16.0) 143.4 (24.1) H = 9.0 0.01b
BP Lying diastolic (mmHg) 80.2 (13.3) 73.9 (7.0) 73.2 (10.2) H = 4.9 0.09
Definite MB lobar 0.1 (0.4) 1.3 (3.7) 0.3 (0.8) H = 7.1 0.03a
Possible MB lobar 0.2 (0.5) 0.4 (1.0) 0.1 (0.3) H = 1.5 0.47
Definite MB deep 0 (0) 0.1 (0.2) 0.0 (0.2) H = 1.0 0.60
Possible MB deep 0 (0) 0 (0) 0.2 (1.1) H = 1.3 0.53
Definite MB cerebellum 0 (0) 0.1 (0.2) 0.0 (0.2) H = 1.0 0.60
Possible MB cerebellum 0 (0) 0 (0) 0.1 (0.3) H = 2.6 0.28
Total MB 0.3 (0.9) 1.8 (4.6) 0.7 (1.3) H = 6.1 0.05a
Any lobar MB [n (%)] 3 (15%) 9 (50%) 7 (23%) χ2 = 6.3 0.04
Any deep MB [n (%)] 0 (0%) 1 (6%) 2 (7%) χ2 = 1.3 0.51
Any cerebellar MB [n (%)] 0 (0%) 1 (6%) 3 (10%) χ2 = 2.2 0.34
Any MB (n (%)) 3 (15%) 9 (50%) 12 (40%) χ2 = 5.6 0.06
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Table 2  DLB microbleed 
present and absent group 
demographics
Mean (SD) or n (%) where specified
Significant findings in bold
CIRS-G Cumulative Illness Rating Scale-Geriatric, FET Fisher’s exact test
Microbleeds absent Microbleeds present Statistic p
n 18 12 – –
Age (years) 74.4 (8.1) 78.8 (3.9) t = − 2.0 0.06
Sex [n (%) female] 4 (22) 3 (25) FET 1
Duration of dementia (months) 25.8 (22.6) 10.4 (4.6) U = 62 0.053
Smoking pack years 14.3 (24.7) 6.3 (11.2) U = 87 0.61
Years in education 10.8 (2.2) 11.8 (5.1) U = 83 0.31
APOE-ɛ4 allele present 11 (61) 6 (55) FET 1
CIRS-G heart score 0.5 (1.0) 0.4 (0.8) U = 108 1
CIRS-G vascular score 1.4 (1.1) 1.2 (1.0) U = 96 0.60
CIRS-G total 11.2 (4.3) 11.8 (3.6) U = 90 0.44
On antiplatelet or warfarin [n (%)] 8 (44) 6 (50) χ2 = 0.1 0.77
On antihypertensive [n (%)] 9 (50) 5 (42) χ2 = 0.2 0.65
On lipid medication [n (%)] 11 (61) 6 (50) χ2 = 0.36 0.55
On cholinesterase inhibitor [n (%)] 16 (89) 11 (92) FET 1
BP Lying Systolic (mmHg) 135.2 (19.0) 155.6 (26.4) U = 55 0.03
BP Lying Diastolic (mmHg) 72.2 (10.5) 74.6 (10.1) t = − 0.6 0.54
Postural systolic BP change (mmHg) − 12.9 (16.8) − 11.4 (32.9) t = − 0.1 0.89
Postural diastolic BP change (mmHg) − 0.5 (10.0) − 1.4 (8.7) t = 0.2 0.81
Table 3  Imaging measures in DLB microbleed present and absent groups
General linear model with age as a covariate. Microbleed present n = 12 for grey matter and hippocampal volume, otherwise n = 11
Significant findings in bold
ICV intracranial volume, SUVR standardised uptake value ratio, WMH white matter hyperintensities, MTL medial temporal lobe
Microbleeds absent Microbleeds present Beta (95% CI) p
n 18 12 – –
Amyloid SUVR 1.25 (0.22) 1.25 (0.24) − 0.17 (− 0.51 to 0.18) 0.33
Grey matter volume (% of ICV) 37.5 (3.2) 36.6 (2.1) 0.03 (− 0.23 to 0.27) 0.88
Hippocampal volume (% of ICV) 0.15 (0.04) 0.15 (0.02) 0.17 (− 0.11 to 0.46) 0.22
Log WMH − 5.1 (1.2) − 4.7 (0.6) 0.07 (− 0.28 to 0.42) 0.68
Parietal perfusion SUVR 0.83 (0.10) 0.93 (0.11) 0.42 (0.04–0.79) 0.03
Occipital perfusion SUVR 0.97 (0.07) 1.02 (0.06) 0.35 (− 0.05 to 0.74) 0.08
MTL perfusion SUVR 0.78 (0.10) 0.78 (0.07) 0.19 (− 0.15 to 0.52) 0.27
Table 4  Baseline cognitive 
and clinical measures in DLB 
microbleed present and absent 
groups
Mean (SD) or percentage where specified. General linear model with age as a covariate
Significant findings in bold
ACE Addenbrooke’s Cognitive Examination, CAF Clinician Assessment of Fluctuation, MDS-UPDRS 
revised Unified Parkinson’s Disease Rating Scale motor sub-scale
Microbleeds absent Microbleeds present Beta (95% CI) p
n 18 12 – –
ACE total 60.1 (15.3) 65.3 (18.8) 0.33 (− 0.03 to 0.68) 0.07
Function z-score 0.19 (1.10) − 0.35 (0.76) − 0.45 (− 0.78 to − 0.11) 0.01
CAF 7.6 (4.3) 4.8 (4.2) − 0.22 (− 0.60 to 0.16) 0.24
MDS-UPDRS 47.9 (17.5) 33.8 (18.0) − 0.40 (− 0.79 to − 0.02) 0.04
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Alzheimer’s disease or cerebral amyloid angiopathy [18]. 
However, these findings contrast with the established link 
between amyloid deposition and microbleeds in healthy 
older people [12, 13]. This association may have a signifi-
cant interaction with age—with amyloid deposition being a 
greater risk factor for microbleed formation in younger ages 
[13]. The amyloid positive group in our study (SUVR > 1.11) 
had a mean age of 78.4 years, which may have been a factor 
in the absence of any association between amyloid SUVR 
and microbleeds.
This study found higher blood pressure in the group with 
microbleeds. This remained significant when age and disease 
duration were included as covariates (data not shown). Hyper-
tension has been reported as a risk factor for deep, but not 
lobar, microbleeds in the Rotterdam Study [11]. However, the 
Mayo Study of Aging reported hypertension to be associated 
with lobar microbleeds, in keeping with our findings [13].
In this study, microbleeds in DLB were predominantly 
lobar. It is unclear if the mechanisms for the development 
of lobar microbleeds are different in healthy older people 
and those with DLB. This is plausible, as people with DLB 
have widespread cortical neurodegeneration, which could 
predispose to the development of microbleeds. De Reuck 
and colleagues [18] have suggested that microbleeds may 
occur in regions of increased angiogenesis related to pathol-
ogy such as Lewy body disease. CSF markers of angiogen-
esis are known to be raised in Parkinson’s disease dementia 
[29], which is pathologically indistinguishable from DLB. It 
is possible that cortical vascular changes in DLB may make 
cortical vessels more susceptible to microbleeds. In such 
conditions, higher systolic blood pressure may be associated 
with a higher risk of microbleeds. Further pathological and 
imaging studies are required to test this hypothesis.
DLB participants with microbleeds had less functional 
impairment, less severe parkinsonism and higher parietal per-
fusion compared to those without microbleeds. However, the 
strength of these associations was attenuated when disease 
duration was included as a covariate and only the associa-
tion with functional impairment remained significant. DLB 
participants with microbleeds had less progression in par-
kinsonism over 1 year. However, there was little difference 
between the two groups and the significance seems driven 
by differences in baseline score. It is difficult to draw conclu-
sions from this clinical data due to the differences in disease 
duration; therefore, we think these findings should be inter-
preted with caution. One possible explanation is that vascu-
lar pathology has additive effects to Lewy body pathology 
in DLB. An additive effect of vascular disease and amyloid 
pathology on cognitive decline in healthy elderly people has 
been reported [30]. In addition, vascular pathology is an inde-
pendent predictor of dementia in AD and synucleinopathy 
[5]. As such, vascular disease may result in the development 
of dementia in the presence of less advanced Lewy body 
pathology than would otherwise be expected in DLB. In such 
circumstances, Lewy body symptoms such as parkinsonism 
may also be less advanced. In the absence of an α-synuclein 
imaging biomarker, this hypothesis is difficult to test in vivo.
Strengths and limitations
This study represents the most thorough assessment to date 
of the relationship of microbleeds with clinical and imaging 
measures in DLB. It is also the only study to report cortical 
amyloid SUVR in conjunction with cerebral microbleeds in 
DLB, providing evidence against the hypothesis that micro-
bleeds in DLB are associated with amyloid pathology. Par-
ticipants were recruited from a range of clinical services and 
have previously been demonstrated to have patterns of cog-
nitive impairment and rates of amyloid deposition in keeping 
with the literature. These findings are therefore generalisable 
to clinical populations. Confirmatory diagnostic biomarkers 
were not assessed as part of this study, but were used to aid 
diagnosis where available.
The prevalence of microbleeds in AD was higher than in a 
recent meta-analysis. This most likely reflects the greater sen-
sitivity of 3T susceptibility-weighted MRI used in this study, 
compared with lower field strengths in previous studies [14]. 
The number of microbleeds present in DLB cases was low, and 
unlikely to be sufficient to be the direct cause of clinical dif-
ferences, but ample evidence shows that the number of micro-
bleeds reported on MRI, even at 3T, underestimates the actual 
numbers present [31]. We compared DLB with possible or 
definite microbleeds to those with no microbleeds, as defined 
by Microbleeds Anatomical Rating Scale. We therefore cannot 
exclude the possibility that some of these microbleeds may 
have been mimics, e.g. calcification or iron deposition.
Due to the relatively low number of microbleeds it was 
not possible to compare amyloid deposition and microbleeds 
in different cortical regions. However, amyloid deposition in 
all regions correlated closely with the mean cortical SUVR 
(r > 0.90 in all areas).
The control group in this study had higher BP than AD 
or DLB. The reasons for this are unclear, though it may 
reflect more intensive medical management of people with 
dementia than healthy older people. Despite this, no healthy 
control had deep microbleeds, for which hypertension is a 
risk factor.
This was an exploratory analysis and therefore statistical 
correction for multiple comparisons across the manuscript 
was not made. The results require validation in other cohorts.
Journal of Neurology 
1 3
Conclusions
Microbleeds in DLB are associated with higher blood pres-
sure, but are not associated with other measures of vascular 
disease or amyloid deposition. The clinical significance of 
microbleeds in DLB remains uncertain.
Acknowledgements This research was supported by the National 
Institute for Health Research (NIHR) Newcastle Biomedical Research 
Centre. Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary 
of Eli Lilly and Company, enabled use of the 18F-florbetapir by pro-
viding tracer and funding scanner time, but was not involved in data 
analysis or interpretation. JO’B is supported by the NIHR Cambridge 
Biomedical Research Centre and the Cambridge Centre for Parkinsons 
Plus Disorders. There are no other financial disclosures or conflicts 
of interest relating to this article. The authors would like to thank the 
staff of the NIHR Clinical Research Network North East and Cumbria 
for their invaluable support with participant recruitment for this study.
Author contribution PCD: 1 A,B,C; 2 A, B, C; 3A. MF: 1 A,B; 2 
A,C; 3B. DM: 1 C; 2 C; 3 B. JL: 1 A; 2 C; 3 B. GP: 1 A; 2 C; 3 B. NB: 
1 B,C; 3 B. KO: 1 B,C; 3 B. AJT: 1 A,B; 2 C; 3 B. JTO’B: 1 A,B; 2 
A,C; 3B. Key: 1. Research project: A. conception, B. organisation, C. 
execution. 2. Statistical analysis: A. design, B. execution, C. review 
and critique. 3. Manuscript preparation: A. writing of the first draft, 
B. review and critique.
Compliance with ethical standards 
Conflicts of interest Dr. Donaghy reports grants from Alzheimer’s 
Research UK and Alzheimer’s Society. Dr. Firbank has nothing to dis-
close. Dr. Mitra reports a grant from the National Institute of Health 
Research. Dr. Lloyd has nothing to disclose. Dr. Petrides reports hono-
raria for educational presentations from GE Healthcare. Ms Barnett 
has nothing to disclose. Ms Olsen has nothing to disclose. Prof. Thom-
as reports grants from Alzheimer’s Research UK, Alzheimer’s Society, 
Economic and Social Research Council, Medical Research Council, 
National Institute of Health Research, Lewy Body Society and GE 
Healthcare. Prof. O’Brien reports grants from Alzheimer’s Research 
UK, Alzheimer’s Society, Medical Research Council and National In-
stitute of Health Research; personal fees from TauRx, Eisai and Axon; 
honoraria from the British Association of Psychopharmacology; Roy-
alties from Taylor and Francis.
Ethical approval This study received ethical approval from the National 
Research Ethics Service Committee North East—Newcastle and North 
Tyneside 2 (13/NE/0064) and was carried out in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki and 
its later amendments.
Informed consent Participants with capacity gave their written 
informed consent to take part in the study. For those who lacked capac-
ity, their participation in the study was discussed with a consultee in 
accordance with the Mental Capacity Act (UK).
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, 
Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, 
Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, 
Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feld-
man H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Gold-
man JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, 
Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis 
S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mol-
lenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O’Brien 
JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, 
Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Tro-
janowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K (2017) 
Diagnosis and management of dementia with Lewy bodies: Fourth 
consensus report of the DLB Consortium. Neurology 89(1):88–
100. https ://doi.org/10.1212/WNL.00000 00000 00405 8
 2. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der 
Flier WM, van Berckel BN, Scheltens P, Visser PJ, Amyloid PET 
Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lam-
mertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau 
SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin 
M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, 
Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, 
Sanchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen 
AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher 
AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chetelat G, 
Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ 
(2015) Prevalence of amyloid PET positivity in dementia syn-
dromes: a meta-analysis. JAMA 313(19):1939–1949. https ://doi.
org/10.1001/jama.2015.4669
 3. Ferman TJ, Aoki N, Crook JE, Murray ME, Graff-Radford NR, 
van Gerpen JA, Uitti RJ, Wszolek ZK, Graff-Radford J, Pedraza 
O, Kantarci K, Boeve BF, Dickson DW (2018) The limbic and 
neocortical contribution of alpha-synuclein, tau, and amyloid beta 
to disease duration in dementia with Lewy bodies. Alzheimer 
Dement 14(3):330–339. https ://doi.org/10.1016/j.jalz.2017.09.014
 4. Jellinger KA (2010) Prevalence and impact of cerebrovascular 
lesions in Alzheimer and Lewy body diseases. Neuro Degener 
Dis 7(1–3):112–115. https ://doi.org/10.1159/00028 5518
 5. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Gross-
man M, Monsell SE, Kukull WA, Trojanowski JQ (2013) Contri-
bution of cerebrovascular disease in autopsy confirmed neurode-
generative disease cases in the National Alzheimer’s Coordinating 
Centre. Brain 136(Pt 9):2697–2706. https ://doi.org/10.1093/brain 
/awt18 8
 6. Sarro L, Tosakulwong N, Schwarz CG, Graff-Radford J, Przybel-
ski SA, Lesnick TG, Zuk SM, Reid RI, Raman MR, Boeve BF, 
Ferman TJ, Knopman DS, Comi G, Filippi M, Murray ME, Parisi 
JE, Dickson DW, Petersen RC, Jack CR Jr, Kantarci K (2017) An 
investigation of cerebrovascular lesions in dementia with Lewy 
bodies compared to Alzheimer’s disease. Alzheimer Dement 
13(3):257–266. https ://doi.org/10.1016/j.jalz.2016.07.003
 7. Ihara M, Polvikoski TM, Hall R, Slade JY, Perry RH, Oakley 
AE, Englund E, O’Brien JT, Ince PG, Kalaria RN (2010) Quan-
tification of myelin loss in frontal lobe white matter in vascular 
dementia, Alzheimer’s disease, and dementia with Lewy bodies. 
Acta Neuropathol 119(5):579–589
 Journal of Neurology
1 3
 8. McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, John-
son M, Beverley JR, Taylor JP, Thomas AJ, O’Brien JT, Attems 
J (2015) Cortical tau load is associated with white matter 
hyperintensities. Acta Neuropathol Commun 3:60. https ://doi.
org/10.1186/s4047 8-015-0240-0
 9. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-
Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler 
MM, Microbleed Study G (2009) Cerebral microbleeds: a guide 
to detection and interpretation. Lancet Neurol 8(2):165–174. https 
://doi.org/10.1016/S1474 -4422(09)70013 -4
 10. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, 
Jager HR, Werring DJ (2009) The microbleed anatomical rating 
scale (mars): reliability of a tool to map brain microbleeds. Neu-
rology 73(21):1759–1766. https ://doi.org/10.1212/WNL.0b013 
e3181 c34a7 d
 11. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Nies-
sen WJ, Hofman A, Krestin GP, Breteler MM (2008) Prevalence 
and risk factors of cerebral microbleeds: the Rotterdam Scan 
Study. Neurology 70(14):1208–1214. https ://doi.org/10.1212/01.
wnl.00003 07750 .41970 .d9
 12. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters 
CL, Rowe CC (2011) Cerebral microhemorrhage and brain beta-
amyloid in aging and Alzheimer disease. Neurology 77(1):48–54. 
https ://doi.org/10.1212/WNL.0b013 e3182 21ad3 6
 13. Graff-Radford J, Botha H, Rabinstein AA, Gunter JL, Przybel-
ski SA, Lesnick T, Huston J 3rd, Flemming KD, Preboske GM, 
Senjem ML, Brown RD Jr, Mielke MM, Roberts RO, Lowe VJ, 
Knopman DS, Petersen RC, Kremers W, Vemuri P, Jack CR Jr, 
Kantarci K (2019) Cerebral microbleeds: Prevalence and relation-
ship to amyloid burden. Neurology 92(3):e253–e262. https ://doi.
org/10.1212/WNL.00000 00000 00678 0
 14. Sepehry AA, Lang D, Hsiung GY, Rauscher A (2016) Prevalence 
of brain microbleeds in Alzheimer disease: a systematic review 
and meta-analysis on the influence of neuroimaging techniques. 
AJNR Am J Neuroradiol 37(2):215–222. https ://doi.org/10.3174/
ajnr.A4525 
 15. Uetani H, Hirai T, Hashimoto M, Ikeda M, Kitajima M, Sakamoto 
F, Utsunomiya D, Oda S, Sugiyama S, Matsubara J, Yamashita 
Y (2013) Prevalence and topography of small hypointense foci 
suggesting microbleeds on 3T susceptibility-weighted imaging in 
various types of dementia. AJNR Am J Neuroradiol 34(5):984–
989. https ://doi.org/10.3174/ajnr.A3332 
 16. Fukui T, Oowan Y, Yamazaki T, Kinno R (2013) Prevalence 
and clinical implication of microbleeds in dementia with Lewy 
bodies in comparison with microbleeds in Alzheimer’s dis-
ease. Dement Geriatr Cogn Dis Extra 3(1):148–160. https ://doi.
org/10.1159/00035 1423
 17. Gungor I, Sarro L, Graff-Radford J, Zuk SM, Tosakulwong N, 
Przybelski SA, Lesnick T, Boeve BF, Ferman TJ, Smith GE, 
Knopman DS, Filippi M, Petersen RC, Jack CR Jr, Kantarci 
K (2015) Frequency and topography of cerebral microbleeds 
in dementia with Lewy bodies compared to Alzheimer’s dis-
ease. Parkinsonism Relat Disord 21(9):1101–1104. https ://doi.
org/10.1016/j.parkr eldis .2015.07.008
 18. De Reuck JL, Auger F, Durieux N, Cordonnier C, Deramecourt 
V, Lebert F, Leys D, Pasquier F, Maurage CA, Bordet R (2015) 
Detection of cortical microbleeds in postmortem brains of patients 
with Lewy body dementia: a 7.0-Tesla magnetic resonance imag-
ing study with neuropathological correlates. Eur Neurol 74(3–
4):158–161. https ://doi.org/10.1159/00044 1057
 19. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman 
H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai 
H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, 
Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, 
Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny 
RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos 
E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-
Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, 
Yamada M (2005) Diagnosis and management of dementia with 
Lewy bodies: third report of the DLB Consortium. Neurology 
65(12):1863–1872. https ://doi.org/10.1212/01.wnl.00001 87889 
.17253 .b1
 20. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR 
Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, 
Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies 
B, Weintraub S, Phelps CH (2011) The diagnosis of dementia 
due to Alzheimer’s disease: recommendations from the National 
Institute on Aging-Alzheimer’s Association workgroups on diag-
nostic guidelines for Alzheimer’s disease. Alzheimer Dement 
7(3):263–269. https ://doi.org/10.1016/j.jalz.2011.03.005
 21. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai 
AH, Mulsant B, Reynolds CF (1992) Rating chronic medical 
illness burden in geropsychiatric practice and research: appli-
cation of the Cumulative Illness Rating Scale. Psychiatry Res 
41(3):237–248
 22. Donaghy PC, Firbank MJ, Thomas AJ, Lloyd J, Petrides G, Bar-
nett N, Olsen K, O’Brien JT (2018) Clinical and imaging corre-
lates of amyloid deposition in dementia with Lewy bodies. Mov 
Disord 33(7):1130–1138. https ://doi.org/10.1002/mds.27403 
 23. Firbank MJ, Minett T, O’Brien JT (2003) Changes in DWI and 
MRS associated with white matter hyperintensities in elderly sub-
jects. Neurology 61(7):950–954
 24. Landau S, Jagust W (2014) Florbetapir processing methods. adni.
bitbucket.org Accessed 13 Jan 2015.
 25. Firbank MJ, Barber R, Burton EJ, O’Brien JT (2008) Validation of 
a fully automated hippocampal segmentation method on patients 
with dementia. Hum Brain Mapp 29(12):1442–1449. https ://doi.
org/10.1002/hbm.20480 
 26. Haacke EM, Xu Y, Cheng YC, Reichenbach JR (2004) Suscepti-
bility weighted imaging (SWI). Magn Reson Med 52(3):612–618. 
https ://doi.org/10.1002/mrm.20198 
 27. Kim SW, Chung SJ, Oh YS, Yoon JH, Sunwoo MK, Hong JY, Kim 
JS, Lee PH (2015) Cerebral Microbleeds in Patients with Demen-
tia with Lewy Bodies and Parkinson Disease Dementia. AJNR 
Am J Neuroradiol 36(9):1642–1647. https ://doi.org/10.3174/ajnr.
A4337 
 28. Sepehry AA, Rauscher A, Hsiung GY, Lang DJ (2016) Micro-
bleeds in Alzheimer’s disease: a neuropsychological overview 
and meta-analysis. Can J Neurol Sci 43(6):753–759. https ://doi.
org/10.1017/cjn.2016.296
 29. Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blen-
now K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos 
E, Cenci MA, Hansson O (2015) Increased CSF biomarkers of 
angiogenesis in Parkinson disease. Neurology 85(21):1834–1842. 
https ://doi.org/10.1212/WNL.00000 00000 00215 1
 30. Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Preboske 
GM, Kantarci K, Raman MR, Machulda MM, Mielke MM, Lowe 
VJ, Senjem ML, Gunter JL, Rocca WA, Roberts RO, Petersen RC, 
Jack CR Jr (2015) Vascular and amyloid pathologies are independ-
ent predictors of cognitive decline in normal elderly. Brain 138(Pt 
3):761–771. https ://doi.org/10.1093/brain /awu39 3
 31. Haller S, Vernooij MW, Kuijer JPA, Larsson EM, Jager HR, 
Barkhof F (2018) Cerebral microbleeds: imaging and clinical 
significance. Radiology 287(1):11–28. https ://doi.org/10.1148/
radio l.20181 70803 
